You are here: Industry Insights > AveXis

News List

Ousted AveXis CSO denies wrongdoing in Novartis data scandal, taps Elon Musk lawyer fiercepharma
August 22, 2019
Novartis’ AveXis has already fired its former chief scientific officer Brian Kaspar in connection with the Zolgensma data manipulation scandal.
AveXis, BIA Ink Gene Therapy Manufacturing Process Development Deal contractpharma
July 29, 2019
BIA to provide expertise in next generation biomolecule purification processes and long-term supply of CIMmultus monolithic columns.
Catalent, AveXis Enter Long-term Strategic Mfg. Pact contractpharma
July 17, 2019
AveXis will have dedicated manufacturing space at Paragon’s new commercial manufacturing center near Baltimore-Washington Int’l Airport.
AveXis’ Zolgensma Aproved for Pediatric Patients with Spinal Muscular Atrophy contractpharma
June 14, 2019
The first and only gene therapy approved by the FDA for the treatment of SMA, including those who are pre-symptomatic at diagnosis.
Zolgensma: First Gene Therapy for Pediatric Spinal Muscular Atrophy (SMA) drugs
June 03, 2019
First Gene Therapy for Pediatric Spinal Muscular Atrophy (SMA).
Clinical Catch-up from Last Week: May 5-10 biospace
May 13, 2019
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
AveXis Presented Robust Data at AAN Demonstrating Efficacy of Zolgensma in Broad Spectrum of Spinal Muscular Atrophy (SMA) Patients drugs
May 08, 2019
AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational product Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)1 that showed positive results across a broad spectrum of patients with spinal muscular atrophy
AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1 drugs
April 18, 2019
AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1.
AveXis Buys Fourth US Plant contractpharma
April 09, 2019
AveXis Buys Fourth US Plant
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado firstwordpharma
April 02, 2019
AveXis, a Novartis company, today announced it signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont……

Previous page 1 2 3 Next page